reviewCurrent Opinion in PharmacologyJun 2, 2015Closed access

PD-1/PD-L1 inhibitors

JSJoel SunshineJMJanis M. Taube

Johns Hopkins University

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

556
total citations
FWCI
24.97
Percentile
100%
References
56
Citations per year

Authors

2

Topics & keywords

Topics
Keywords
  • Pembrolizumab
  • Nivolumab
  • Medicine
  • Melanoma
  • PD-L1
  • Clinical trial
  • Renal cell carcinoma
  • Lung cancer
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.